Acquisition will add to Dover’s single-use part providing

pressure gauge octa has entered right into a definitive settlement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s merchandise will expand Dover’s biopharma single-use production providing, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate approximately US$40 million–45 million in revenue in the course of the full yr 2022.
When the deal closes, Malema will turn out to be part of the PSG enterprise unit within Dover’s Pumps & Process Solutions section.
“We see an amazing long-term growth opportunity within the bioprocessing business pushed by a powerful and growing pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as properly as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, digital pressure gauge growing adoption of more environment friendly single-use production processes supports a robust outlook for our choices of single-use parts to end-customers. We consider that pairing Malema’s technology with our current portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our solutions to our prospects.”

“We are methodically constructing out our biopharma platform by way of proactive capability additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest part applied sciences,” said Richard Tobin, president and CEO of Dover. “ เกจวัดแรงดัน represents a strategic and highly-complementary flow-control and sensing technology and further strengthens our sensor portfolio with new proprietary technology. In addition to enticing biopharma applications, we anticipate robust progress within the semiconductor space on the capability growth and re-shoring tailwinds.”

Share

Scroll to Top